The specter of generic competition has repeatedly loomed above copyright’s famous drug, Sildenafil, raising questions about the future of similar pharmaceutical portfolios. While first periods saw impressive profits, the intellectual property expiration has allowed the door for discounted alternatives, potentially lowering revenue and presenting… Read More